【摘要】 目的探讨碳酸酐酶Ⅸ(CAⅨ/G250)在肾癌组织和血液中的表达情况和临床意义。方法采用RT-PCR技术检测62例肾癌患者癌组织和外周血液中碳酸酐酶Ⅸ(G250)mRNA的表达,以32例正常肾组织和非肾癌患者外周血作为对照。结果 62例肾癌患者碳酸酐酶Ⅸ(G250)mRNA阳性率在癌组织中为82.3%(51/62),在外周血中为54.8%(34/62),各对照组均无阳性表达,差异有统计学意义(P<0.05);在肾透明细胞癌患者癌组织和外周血中碳酸酐酶Ⅸ(G250)mRNA阳性率分别为98%(49/50)和66%(33/50),显著高于其他类型肾癌(P<0.05)。结论碳酸酐酶Ⅸ(G250)在肾癌尤其是透明细胞癌中有特异性的高表达,可以用于肾癌以及肾癌微转移的诊断和预后评价。更多还原

【Abstract】 Objective To investigate the expression and clinical significance of CAⅨ mRNA in patients with renal cell carcinoma(RCC).Methods Reverse-transcription polymerase chain reaction was performed to detect CAⅨ mRNA in carcinoma tissue and peripheral blood from patients with RCC(n=62),normal tissue and peripheral blood sample(n=32)as control.Results CAⅨ mRNA positive rates were 82.3%(51/62)in renal carcinoma tissues and 54.8%(34/62)in peripheral blood from patients with RCC,which were significantly higher than that of the control cases(P<0.05).CAⅨ mRNA positive rates were 98%(49/50)in carcinoma tisuues and 66%(33/50)in peripheral blood from patients with clear cell renal cell carcinoma,which were significantly higher than that of non-clear cell type of RCC(P<0.05).Conclusions CAⅨ mRNA detected by RT-PCR assay is reliable to RCC especially to clear cell RCC.It could be a useful parameter for RCC diagnosis,micrometastasis detection and therapeutic evaluation.更多还原